Judge’s 340B Statutory Interpretation Was “Exactly Backward,” Lilly Tells Appeals Court

Lilly wordmark on exterior sign
Lilly told a federal appeals court its decision in the drug company's 340B contract pharmacy lawsuit "will have profound consequences for the integrity of the national healthcare system."

A federal district court’s ruling last October that federal law requires drug manufacturers to deliver 340B purchased drugs to contract pharmacies conflicts with two other courts’ conclusions, “upsets the delicate statutory balance Congress struck, and raises serious constitutional problems,” drug

Read More »

Groups Blast PBMs’ Discrimination Against 340B Hospitals in Letters to FTC

Federal Trade Commission building
Groups that represent or work with 340B hospitals urged the FTC to take a closer look at PBMs' alleged discriminatory business practices.

Pharmacy benefit managers’ discriminatory business practices against 340B hospitals boost PBMs’ financial bottom lines while hurting the hospitals’ mission to serve vulnerable patients, groups that represent or work with 340B hospitals and their pharmacists recently told the Federal Trade Commission

Read More »

340B Report Publisher and CEO: Momentum for 340B Protections Is Growing

Interior of Washington State House of Representatives chamber
340B healthcare providers have turned to the states to address challenges to the drug discount program, 340B Report Publisher and CEO Ted Slafsky says.

Safety net healthcare providers increasingly have turned to the states to address challenges to the 340B program, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.

“In just four years, an

Read More »

NEJM Article Says HIV Prevention Should Rely Less on 340B Revenue

screenshot of a New England Journal of Medicine article
An opinion article in the New England Journal of Medicine says overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options. Some HIV/AIDS care providers say high drug prices are the problem, not 340B.

Overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options, “with dire consequences for [preexposure prophylaxis] PrEP access, impact, and equity,” says an opinion article published last weekend in

Read More »

BMS and Merck Announce Refunds for 340B Overcharges

an extended hand holding a 100 dollar bill
BMS and Merck—both for the second time this year—are giving 340B covered entities refunds for overcharges on select products.

Drug manufacturers Bristol Myers Squibb (BMS) and Merck are giving 340B covered entities refunds for overcharges on select products, according to public notices by the companies posted on the U.S. Health Resources and Services Administration (HRSA) website.

BMS

For the

Read More »

With Talk of Legislation Heating Up, PhRMA Seeks a New 340B Policy Director

PhRMA wordmark repeated on a background
PhRMA is seeking a new director for its policy and research team to help develop and lead implementation of work on 340B.

Pharmaceutical Research and Manufacturers of America (PhRMA) is seeking a new director for its policy and research team to help develop and lead implementation of work on 340B and related hospital cost and affordability issues, according to an employment solicitation

Read More »

340B ADR Proposed Rule Remains at White House 5 Months Past Expected Publication Date

Pages of a calendar
A proposed replacement for the 340B administrative dispute resolution process has been under White House review for more than six months.

A proposed replacement for the 340B administrative dispute resolution (ADR) process has been under White House review for more than half a year. It seems to be no closer to publication for notice and comment than it was when it

Read More »

CMS Asks Court Again to Dismiss 340B Health Centers’ Suit Over Medicaid Drug Benefits Transfer

A state of California benefits identification card
CMS again asked a federal district court to dismiss California 340B health centers’ lawsuit over the state’s transfer of Medicaid managed care drug benefits to Medicaid fee for service.

The U.S. Centers for Medicare & Medicaid Services (CMS) last week again asked a federal district court in Sacramento to dismiss a group of California health centers’ claims for relief over CMS’s approval of the state’s transfer of Medicaid managed

Read More »

Tennessee Health System Strikes Back Against DOJ Claims It Paid for Referrals to Boost 340B Revenue

Methodist University Hospital, Methodist Le Bonheur Healthcare building
Methodist Le Bonheur Healthcare disputes U.S. Justice Department claims that the health system's agreements under the system’s affiliation with a private oncology practice were “a fiction” perpetuated partially to let the system “realize profits from the 340B program.”

A Tennessee health system last week denied U.S. Justice Department (DOJ) allegations that agreements under the system’s seven-year affiliation with a private oncology practice were “a fiction” perpetuated partially to let the system “realize profits from the 340B program.”

Methodist

Read More »

Provider Groups File Appellate Briefs in Key 340B Contract Pharmacy Cases

US court of appeals for the DC circuit courtroom interior
Groups representing health centers, HIV/AIDS clinics, and hospitals filed briefs in key 340B contract pharmacy cases in federal appeals courts in Washington, D.C., and Philadelphia.

Groups representing health centers, HIV/AIDS clinics, and hospitals asked federal appeals courts in Philadelphia and Washington, D.C., this week to hold that drug manufacturers must give covered entities 340B discounts on drugs when entities use contract pharmacies to fill prescriptions

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report